About C1GALT1-specific chaperone 1
C1GALT1-specific chaperone 1 (C1GALT1C1) is a protein
from Homo sapiens identified by UniProt accession
Q96EU7, 318 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | C1GALT1-specific chaperone 1 |
|---|
| UniProt accession | Q96EU7 |
|---|
| Gene | C1GALT1C1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 318 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- hemolytic uremic syndrome, atypical, 8, with rhizomelic short stature · score 0.51
- neurodegenerative disease · score 0.46
- carcinoma · score 0.37
- atypical hemolytic-uremic syndrome · score 0.34
- Abnormal protein O-linked glycosylation · score 0.27
- IGA glomerulonephritis · score 0.08
- breast cancer · score 0.08
- cancer · score 0.05
- neoplasm · score 0.04
- congenital factor X deficiency · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96EU7-F1 | alphafold | PREDICTED | 87.17 | — |
Amino-acid sequence (318 residues)
MLSESSSFLK GVMLGSIFCA LITMLGHIRI GHGNRMHHHE HHHLQAPNKE DILKISEDER MELSKSFRVY CIILVKPKDV SLWAAVKETW TKHCDKAEFF SSENVKVFES INMDTNDMWL MMRKAYKYAF DKYRDQYNWF FLARPTTFAI IENLKYFLLK KDPSQPFYLG HTIKSGDLEY VGMEGGIVLS VESMKRLNSL LNIPEKCPEQ GGMIWKISED KQLAVCLKYA GVFAENAEDA DGKDVFNTKS VGLSIKEAMT YHPNQVVEGC CSDMAVTFNG LTPNQMHVMM YGVYRLRAFG HIFNDALVFL PPNGSDND
Explore C1GALT1-specific chaperone 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets